Bevacizumab

Journal of Clinical Oncology P

12 years ago

Serious Bevacizumab-Associated Gastrointestinal Toxicity

bevacizumab

ovariancancer

gastrointestinaltoxicity

antiangiogenicagents

phase3trials

+5

+4

+4

+4

+3

+3

+3

+3

+2

bevacizumab

ovariancancer

gastrointestinaltoxicity

antiangiogenicagents

phase3trials

+5

+4

+4

+4

+3

+3

+3

+3

+2

Journal of Clinical Oncology P

13 years ago

A Clear Answer to the Wrong Question

bevacizumab

pemetrexed

nonsmallcelllungcancer

maintenancetherapy

continuationmaintenancetherapy

+5

+4

+4

+4

+3

+3

+3

+2

+2

bevacizumab

pemetrexed

nonsmallcelllungcancer

maintenancetherapy

continuationmaintenancetherapy

+5

+4

+4

+4

+3

+3

+3

+2

+2

Squamous Lung Cancer Part 5, Q and A Session (audio)

GRACEcast Lung Cancer Audio

12 years ago

Squamous Lung Cancer Part 5, Q and A Session (audio)

grace

cancergrace

kras

bevacizumab

gemcitabine

+4

+4

+4

+3

+2

+2

+2

+1

13:57

grace

cancergrace

kras

bevacizumab

gemcitabine

+4

+4

+4

+3

+2

+2

+2

+1

Journal of Clinical Oncology P

12 years ago

The Efficacy of Bevacizumab Combined with Chemotherapy for Platinum-Resistant Recurrent Ovarian Canc

bevacizumab

ovariancancer

aureliatrial

qualityoflife

patientreportedoutcomes

+5

+4

+4

+4

+3

+3

+3

+2

+1

bevacizumab

ovariancancer

aureliatrial

qualityoflife

patientreportedoutcomes

+5

+4

+4

+4

+3

+3

+3

+2

+1

The Lancet Oncology: August 02, 2010

Listen to The Lancet Oncology

16 years ago

The Lancet Oncology: August 02, 2010

lung cancer

bevacizumab

veg f

bmi

obesity

+5

+4

+4

+4

+3

+2

+2

lung cancer

bevacizumab

veg f

bmi

obesity

+5

+4

+4

+4

+3

+2

+2

Mini-Symposium on the Management of AMD, Neovascular Age-Related Macular Degeneration: Initial Manag

AMD eSeminar Series

16 years ago

Mini-Symposium on the Management of AMD, Neovascular Age-Related Macular Degeneration: Initial Manag

ranibizumab

photodynamic

therapy using verteporfin

bevacizumab

marinaanchor

+5

+4

+4

+4

+3

+3

+3

+3

+2

ranibizumab

photodynamic

therapy using verteporfin

bevacizumab

marinaanchor

+5

+4

+4

+4

+3

+3

+3

+3

+2

Cancer Network Podcasts

14 years ago

Bevacizumab Plus Chemotherapy in Patients With Early Stage HER2-Negative Breast Cancer

oncology

breast cancer

triple-negative

bevacizumab

nejm

+5

+4

+4

+4

+3

+3

+3

+2

10:44

oncology

breast cancer

triple-negative

bevacizumab

nejm

+5

+4

+4

+4

+3

+3

+3

+2

Journal of Clinical Oncology P

15 years ago

RIBBON-1 Revisited

chemotherapy

antiangiogenesis

metastatic

bevacizumab

breastcancer

+5

+5

+4

+4

+4

+3

+3

+2

+2

chemotherapy

antiangiogenesis

metastatic

bevacizumab

breastcancer

+5

+5

+4

+4

+4

+3

+3

+2

+2

Mini-Symposium on the Management of AMD, Neovascular Age-Related Macular Degeneration: Case Presenta

AMD eSeminar Series

16 years ago

Mini-Symposium on the Management of AMD, Neovascular Age-Related Macular Degeneration: Case Presenta

ranibizumab

bevacizumab

visual acuity

fluorescein angiograms

choroidal neovascularization

+5

+4

+4

+4

+3

+3

+3

+2

+1

ranibizumab

bevacizumab

visual acuity

fluorescein angiograms

choroidal neovascularization

+5

+4

+4

+4

+3

+3

+3

+2

+1

Breast cancer: The Lancet Oncology: Aug 6, 2015

Listen to The Lancet Oncology

11 years ago

Breast cancer: The Lancet Oncology: Aug 6, 2015

breast cancer

bevacizumab

avastin

surgery

chemotherapy

+5

+5

+4

+4

+3

+3

+2

+2

breast cancer

bevacizumab

avastin

surgery

chemotherapy

+5

+5

+4

+4

+3

+3

+2

+2